IntroductionThis prospective study aimed to determine whether trimetazidine (TMZ) alters the pharmacodynamic (PD) effects of clopidogrel.MethodsPatients with stable coronary artery disease (SCAD) (n = 24) who were actively treated with dual antiplatelet therapy (DAPT) of aspirin 81 mg daily and clopidogrel 75 mg daily were recruited. Platelet function was measured with the VerifyNow P2Y12 assay (Accriva Diagnostics, San Diego, CA, USA) and assessed before the initiation of and after 14 days of treatment with TMZ. Results were compared using a paired t test.ResultsAlmost 80% of the study population were of South Asian descent and had diabetes mellitus (DM). P2Y12 reaction units (PRUs) were higher in patients on TMZ (204 ± 56 compared with 174 ± 71 before TMZ, p = 0.005). The average increase in PRU score was 29 (95% confidence interval 8.8–49.7). Before TMZ, the proportion of patients with high on-treatment platelet reactivity (PRU > 208 units) was 25%, which increased to 42% for patients on TMZ.ConclusionHigher platelet reactivity was seen in patients on TMZ, suggesting that TMZ attenuated the PD effects of clopidogrel in this study of a predominantly South Asian diabetic subpopulation. Alternative therapies should be considered and further research is warranted.Trial RegistrationClinicalTrials.gov number, NCT03603249.

Abbreviations: (FPG) This results in the urgent need for cheap and effective screening and diagnostic methods. Although several are available, fasting plasma glucose (FPG) is routinely used both for monitoring and for diagnosing diabetes mellitus. The use of FPG is inconvenient for the patient, as it requires a 12 h fast.2 Glycated hemoglobin is now recommended for the diagnosis of diabetes mellitus.2,3 The benefits of the hemoglobin A1c (HbA1c) assay include relative stability of samples after collection, sample collection is convenient because a fasting period is not required, and samples can be randomly obtained. These factors have supported the use of HbA1c instead of FPG and 2 h glucose. The study compared the diagnosis of type 2 diabetes mellitus (T2DM) using FPG with HbA1c among patients seen in a primary care setting in which a first-time diagnosis of diabetes was contemplated without existing morbidities.Patients with no prior confirmation of T2DM were eligible for entry into the study. Of the 308 patients entered into the study using a FPG >128 mg/dl, 102 (33.1%) were classified as having T2DM, 64 (20.8%) were classified as having impaired fasting glucose (110-125 mg/dl), and the remaining 142 (46.1%) were classified as euglycemic (plasma glucose <110 mg/dl). On the other hand, 152 (49.4%) participants had a HbA1c assay >6.5% and were classified as having T2DM. In other words, more participants (50; 16%) were classified with diabetes using HbA1c ( Table 1).The study observed the poor performance of the FPG compared with HbA1c in the diagnosis of diabetes mellitus. The implication of this finding is that 42.76% of patients who were referred for a FPG only and may truly have T2DM will remain undiagnosed. These findings are consistent with Kim and associates. 4 Our study showed the poor correlation (r = 0.02) between FPG and HbA1c for values of FPG <126 mg/dl, indicating that, at the current cutoff point of 126 mg/dl, the FPG was unreliable compared with HbA1c. Perry and colleagues 5 also showed that using HbA1c assay increased the sensitivity of diagnosis for values of FPG greater than 126 mg/dl. Therefore, for patients with FPG close to 126 mg/dl, it should be mandatory to also have a HbA1c assessment. On the other hand, when the FPG exceeded 126 mg/dl, the correlation was significantly stronger, r = 0.72 (p ≤ .05). The proportion of patients diagnosed with diabetes using HbA1c criteria (49.4%) was significantly larger than for FPG (33.1%) criteria (p < .01). In conclusion, against a HbA1c ≥6.5%, for a single fasting glucose ≥126 mg/dl, the sensitivity and specificity for detection of diabetes were 57% and 90%, respectively (area under the curve, 0.79). Hemoglobin A1c classified more people as having diabetes (49.4%) compared with FPG (33.1%). LETTER TO EDITORAcknowledgments: